GLUT1 glucose transporter: A highly sensitive marker of malignancy in body cavity effusions

Modern Pathology

Volumn 11, Issue 4, 1998, Pages 392-396

  Burstein, David E ^a   Reder, Ilan ^a   Weiser, Kenneth ^a   Tong, Tommy ^a   Pritsker, Alla ^a   Haber, Richard S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Body cavity effusions; Carcinoma; Cytopathology; Glucose transporters; GLUT1; Immunocytochemistry; Tumor markers

Indexed keywords

GLUCOSE TRANSPORTER;

ARTICLE; BENIGN TUMOR; CANCER CYTODIAGNOSIS; DIFFERENTIAL DIAGNOSIS; EFFUSION; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

CARCINOMA; DATA INTERPRETATION, STATISTICAL; ERYTHROCYTES; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MONOSACCHARIDE TRANSPORT PROTEINS; NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0031969977     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Warburg O. On the origin of cancer cells. Science 1956;123: 309-14.
2. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-48.
3. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223-30.
4. Nagase Y, Takata K, Moriyama N, Aso Y, Murakami T, Hirano H. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. J Urol 1995;153:798-801.
5. Mellanen P, Minn H, Grenman R, Harkonen P. Expression of glucose transporters in head-and-neck tumors. Int J Cancer 1994;56:622-9.
6. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter GLUT1 in human cancers. Cancer Res 1996;56:1164-7.
7. Haber RS, Weiser KR, Pritzker A, Reder I, Burstein DE. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 1997;7:363-7.
8. Pessin JE, Bell GI. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol 1992;54:911-30.
9. Pardridge W, Boado R, Farrell C. Brain-type glucose transporter (GLUT1) is selectively localized to the blood-brain-barrier. J Biol Chem 1990;265:18035-40.
10. Froehner SC, Davies A, Baldwin SA, Lienhard GE. The blood-nerve barrier is rich in glucose transporter. J Neurocytol 1988;17:173-8.
11. Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H. Localization of erythrocyte/HepG2-type glucose transporter (GLUT1) in human placental villi. Cell Tissue Res 1992;267:407-12.
12. Frisman DM, McCarthy WF, Schleiff P, Buckner S, Nocito JD, O'Leary TJ. Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations. Mod Pathol 1993;6:179-84.
13. Haspel HC, Rosenfeld MG, Rosen OM. Characterization of antisera to a synthetic carboxyl-terminal peptide of the glucose transporter protein. J Biol Chem 1988;263:398-403.
14. Berek JS, Hacker NF. Practical gynecologic oncology. Baltimore: Williams & Wilkins; 1988. p. 331-2.
15. Kohn ED, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995; 55:1856-62.
16. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
17. Good JT, Taryle DA, Sahn SA. Pathogenesis of low glucose / low pH malignant effusions. Am Rev Respir Dis 1985;131: 737-41.
18. Sahn SA, Good JT. Pleural fluid pH in malignant effusions. Ann Intern Med 1988;108:345-9.
19. Haber RS, Rathan A, Weiser KR, Pritsker A, Hzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998;82 (in press).
20. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. GLUT1 and GLUT3 are significant prognostic indicators in stage 1 non-small cell lung carcinoma [abstract]. Lab Invest 1996;74:165A.
21. Juarez D, Lechago LV, Somoano J, Younes M. GLUT1 expresion in transitional cell carcinoma of the urinary bladder correlates with aggressive biologic behavior [abstract]. Lab Invest 1996;74:75A.
22. Goldfischer M, Weiser K, Pritsker A, Haber R, Burstein D. GLUT1 glucose transporter expression in ovarian neoplasms: a marker of tumor progression [abstract]. Lab Invest 1996;74:90A.
23. Burstein DE, Reder I, Miller L, Hauptman E. GLUT1: a more sensitive and selective marker of malignancy than CEA in body cavity effusions and washes [abstract]. Acta Cytol 1996; 40:1054-5.
24. Hue L, Rousseau GG. Fructose 2,6 biphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes. Adv Enzyme Regul 1993;33:97-110.
25. Board M, Colquhoun A, Newsholme EA. High Km glucose-phosphorylating (glucokinase) activities in a range of tumor cell lines and inhibition of rates of tumor growth by the specific enzyme inhibitor mannoheptulose. Cancer Res 1995;55:3278-85.
26. Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H, et al. Distribution of the glucose transporters in human brain tumors. Cancer Res 1992;52:3972-9.
27. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras and src oncogenes. Science 1987;235:1492-5.
28. Sivitz WI, Lund DD, Yorek B, Grover-McKay M, Schmid PG. Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia. Am J Physiol 1992; 263:E562-E569.